PHILADELPHIA--(BUSINESS WIRE)--Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Doxycycline Tablets, 75 mg and 150 mg, the generic equivalent of Adoxa® marketed by Par Pharmaceutical, Inc. According to Wolters Kluwer, combined sales of generic Doxycycline Tablets, 75 mg and 150 mg, were $25.8 million in 2007.
